Bedrijfsoverzicht
Intellia Therapeutics, Inc. is a clinical-stage gene editing company dedicated to the development of curative genome editing treatments designed to address specific genetic conditions. Operating within the Healthcare sector and the Biotechnology industry, the company focuses on advancing therapeutic interventions that aim to modify genetic material directly within the body or at the cellular level. The firm employs 377 individuals and holds a market capitalization of $1.59B, generating annual revenue of $67.67M according to trailing twelve-month figures. These financial metrics indicate that the company operates as a significant player in the specialized biotechnology space, yet its market cap relative to its revenue suggests a valuation that heavily weights future potential and intellectual property value rather than current profitability. The substantial market cap of $1.59B reflects significant investor confidence in the long-term viability of its pipeline, while the revenue scale of $67.67M demonstrates an established, though not yet mature, commercial operation. With a workforce of 377 employees, the company maintains a lean organizational structure typical of clinical-stage biotechs, allowing for agile development of its in vivo programs like NTLA-2001 and NTLA-2002.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $67.67M, yet it recorded a net income of -$412,694,016 and an EBITDA of -$431,223,008, revealing a cost structure where operational expenses significantly exceed total revenue. This substantial gap indicates that the business is in a heavy investment phase, likely driven by research and development costs associated with its gene editing technology. Free cash flow stands at -$233,285,744, which implies that the company is currently burning cash to fund its operations and clinical trials rather than generating cash reserves from daily activities. The gross margin is listed as 0.0%, while the operating margin is -428.9% and the profit margin is 0.0%, collectively indicating that the company has not yet achieved profitability and faces significant scaling challenges typical of early-stage biotechnology firms. Despite the negative earnings, the balance sheet shows a cash position of $449.88M against total debt of $93.33M, resulting in a debt-to-equity ratio of 13.90. This high ratio suggests a leveraged balance sheet in accounting terms, yet the significant cash buffer provides a conservative safety net against the high debt load. The current ratio of 5.08 indicates strong short-term liquidity, as the company holds assets well in excess of its current liabilities, ensuring it can meet immediate obligations. Furthermore, the return on equity is -53.5% and the return on assets is -27.1%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and in the company's assets.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E stands at -4.62, implying that the market is pricing in future earnings that are currently projected to remain negative or are not yet materialized. The price-to-book ratio is 2.34, indicating that the stock trades at a premium of 134% over its book value, which often occurs in biotechnology firms where intangible assets like patents are not fully captured on the balance sheet. The price-to-sales ratio is 23.55 and the EV/EBITDA is -2.87, suggesting that investors are valuing the company primarily on its revenue generation potential and pipeline value rather than current earnings power. The 52-week high is $28.25 and the 52-week low is $6.73, meaning the current valuation fluctuates within a range that highlights significant recent volatility and investor sentiment shifts regarding the clinical progress of its assets. The beta value of 1.99 indicates that the stock is highly volatile, moving nearly twice as much as the broader market in either direction. This high sensitivity to market movements is characteristic of small-to-mid-cap biotechnology companies where news regarding clinical trials can cause drastic price swings.
Growth & Income
Revenue growth year-over-year stands at 78.8%, while earnings growth is N/A due to the company's current losses, indicating that top-line expansion is outpacing profitability which is expected in the early commercialization phase. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available cash flow back into research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage companies that prioritize funding their in vivo programs over providing immediate returns to investors. The overall growth and income profile is defined by aggressive revenue expansion coupled with a complete absence of current earnings or dividend income, reflecting a high-risk, high-reward investment thesis centered on future product approvals.